Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Publikation: Bidrag til tidsskriftTidsskriftartikelForskning

DOI

  1. Fast-track pneumonia pathway focusing on early progressive mobilisation: a clinical feasibility study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sharing and reuse of individual participant data from clinical trials: principles and recommendations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Early vasopressor use following traumatic injury: a systematic review

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men without Diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Metformin-induced changes of the gut microbiota in healthy young men: results of a non-blinded, one-armed intervention study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. The impact of schizophrenia and intelligence on the relationship between age and brain volume

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight-lowering effects have also been recognised in patients with non-diabetes. The primary endpoint of this trial is weight loss after 3 months of treatment with a GLP-1 receptor agonist (exenatide once weekly) in patients with non-diabetic schizophrenia with antipsychotic-associated obesity. Secondary endpoints include physiological and metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain MRI.
OriginalsprogEngelsk
TidsskriftB M J Open
Vol/bind4
Udgave nummer1
Sider (fra-til)e004158
ISSN2044-6055
DOI
StatusUdgivet - 2014

ID: 42313686